ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
FTSE 100
8,673.96
0.31%
Dow Jones
44,615.88
-0.59%
Gold vs US Dollar
2,798.75
0.11%
Brent Oil
76.02
-0.04%
Bitcoin
102,651.05
-1.99%
Pepperstone
Advertisement
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Panbela Therapeutics Inc (PBLA)

  7. Panbela Therapeutics Inc (PBLA) News

Panbela Therapeutics (PBLA)

Panbela Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:PBLA
DateTimeSourceHeadlineSymbolCompany
24/09/202412:00GlobeNewswire Inc.First Patient Enrolled in Phase I Program in STK11 Mutant Non-Small Cell Lung Cancer at Moffitt Cancer CenterNASDAQ:PBLAPanbela Therapeutics Inc
16/08/202421:25Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:PBLAPanbela Therapeutics Inc
13/08/202420:10GlobeNewswire Inc.Panbela Provides Business Update and Reports Q2 2024 Financial ResultsNASDAQ:PBLAPanbela Therapeutics Inc
30/07/202421:30Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:PBLAPanbela Therapeutics Inc
30/07/202420:59Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PBLAPanbela Therapeutics Inc
03/07/202420:46Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PBLAPanbela Therapeutics Inc
24/06/202412:00GlobeNewswire Inc.Panbela Therapeutics Announces Third Independent Safety Review of Phase 3 ASPIRE Clinical Trial DSMB Recommended Continuation with No Trial ModificationNASDAQ:PBLAPanbela Therapeutics Inc
10/06/202412:00GlobeNewswire Inc.Panbela Announces Oral Presentation at Digestive Disease Week (DDW):NASDAQ:PBLAPanbela Therapeutics Inc
29/05/202411:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PBLAPanbela Therapeutics Inc
15/05/202420:10GlobeNewswire Inc.Panbela Provides Business Update and Reports Q1 2024 Financial ResultsNASDAQ:PBLAPanbela Therapeutics Inc
06/05/202412:00GlobeNewswire Inc.Panbela Announces Issuance of New Patent in the US and Canada; Patent is for Claims of a Fixed Dose Combination of Eflornithine and SulindacNASDAQ:PBLAPanbela Therapeutics Inc
01/05/202420:15GlobeNewswire Inc.Panbela to Host First Quarter 2024 Earnings Conference Call on May 15, 2024NASDAQ:PBLAPanbela Therapeutics Inc
30/04/202412:00GlobeNewswire Inc.Acceptance of Eflornithine (DFMO) Abstract for Oral Presentation at Digestive Disease WeekNASDAQ:PBLAPanbela Therapeutics Inc
26/04/202420:39Edgar (US Regulatory)Form PRER14A - Preliminary Proxy Soliciting materialsNASDAQ:PBLAPanbela Therapeutics Inc
25/04/202420:36Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:PBLAPanbela Therapeutics Inc
25/04/202420:35Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PBLAPanbela Therapeutics Inc
25/04/202413:09Edgar (US Regulatory)Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securitiesNASDAQ:PBLAPanbela Therapeutics Inc
22/04/202412:02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PBLAPanbela Therapeutics Inc
22/04/202412:00GlobeNewswire Inc.Panbela Therapeutics Announces Interim Data Analysis for ASPIRE Trial Pushed to Q1 2025NASDAQ:PBLAPanbela Therapeutics Inc
18/04/202420:31Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:PBLAPanbela Therapeutics Inc
18/04/202412:00GlobeNewswire Inc.Panbela Announces Poster Presentation at American Association for Cancer Research:NASDAQ:PBLAPanbela Therapeutics Inc
17/04/202412:36Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PBLAPanbela Therapeutics Inc
17/04/202404:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:PBLAPanbela Therapeutics Inc
16/04/202421:29GlobeNewswire Inc.Panbela Announces Transfer to OTCQB MarketNASDAQ:PBLAPanbela Therapeutics Inc
04/04/202420:17Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:PBLAPanbela Therapeutics Inc
03/04/202404:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:PBLAPanbela Therapeutics Inc
29/03/202421:24Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:PBLAPanbela Therapeutics Inc
29/03/202421:08Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:PBLAPanbela Therapeutics Inc
26/03/202420:15Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:PBLAPanbela Therapeutics Inc
26/03/202420:12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PBLAPanbela Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:PBLA

Your Recent History

BIT
UC7T71
Unicredit Bank
BIT
UC7Z1A
Unicredit Bank
BIT
UC9154
Unicredit Bank
BIT
P15T14
BNP Paribas Issuance
BIT
F37513
Vontobel Financial Produ...
BIT
P1LOA9
BNP Paribas Issuance
BIT
C00175
Commerzbank
BIT
UIJ073
Unicredit Bank
BIT
P13VQ8
BNP Paribas Issuance
BIT
P1JIG2
BNP Paribas Issuance
BIT
UB87QE
Unicredit Bank
BIT
I08109
Intesa Sanpaolo
BIT
1PLTR
Palantir Technologies
NYSE
BHR
Braemar Hotels and Resorts
USOTC
PZARF
Paz Ashdod Refinery (PK)
BIT
I06794
Intesa Sanpaolo
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2025 ADVFN PLC - All Rights Reserved

    Go Ad-Free

    Subscribe to Ad free and enjoy an ad-free experience

    No Ads

    Try Now

    Keep the Ads